Moody National Bank Trust Division Purchases Shares of 1,661 Illumina, Inc. (NASDAQ:ILMN)

Moody National Bank Trust Division purchased a new stake in shares of Illumina, Inc. (NASDAQ:ILMNGet Rating) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,661 shares of the life sciences company’s stock, valued at approximately $306,000.

Other hedge funds also recently bought and sold shares of the company. B. Metzler seel. Sohn & Co. AG boosted its holdings in Illumina by 2.7% during the first quarter. B. Metzler seel. Sohn & Co. AG now owns 12,505 shares of the life sciences company’s stock valued at $4,369,000 after acquiring an additional 331 shares during the period. Allworth Financial LP lifted its stake in shares of Illumina by 155.5% in the first quarter. Allworth Financial LP now owns 304 shares of the life sciences company’s stock valued at $106,000 after buying an additional 185 shares during the period. Farmers & Merchants Investments Inc. bought a new stake in shares of Illumina in the first quarter valued at about $30,000. Prudential PLC lifted its stake in shares of Illumina by 4.4% in the first quarter. Prudential PLC now owns 6,451 shares of the life sciences company’s stock valued at $2,254,000 after buying an additional 271 shares during the period. Finally, NEXT Financial Group Inc lifted its stake in shares of Illumina by 4.0% in the fourth quarter. NEXT Financial Group Inc now owns 3,916 shares of the life sciences company’s stock valued at $1,490,000 after buying an additional 151 shares during the period. 86.12% of the stock is currently owned by institutional investors.

Illumina Trading Down 0.5 %

NASDAQ ILMN opened at $198.81 on Tuesday. The firm has a market cap of $31.23 billion, a P/E ratio of -3,312.95, a P/E/G ratio of 2.29 and a beta of 1.16. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.00 and a quick ratio of 0.82. The stock’s 50-day moving average is $206.02 and its 200-day moving average is $250.21. Illumina, Inc. has a one year low of $173.45 and a one year high of $449.99.

Illumina (NASDAQ:ILMNGet Rating) last released its quarterly earnings results on Thursday, August 11th. The life sciences company reported $0.57 EPS for the quarter, missing analysts’ consensus estimates of $0.63 by ($0.06). The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.22 billion. Illumina had a positive return on equity of 5.61% and a negative net margin of 0.43%. The company’s revenue for the quarter was up 3.2% compared to the same quarter last year. During the same period in the prior year, the business earned $1.87 EPS. Sell-side analysts anticipate that Illumina, Inc. will post 2.81 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on ILMN. Atlantic Securities reduced their target price on shares of Illumina to $190.00 in a research note on Monday, August 15th. Credit Suisse Group assumed coverage on Illumina in a report on Wednesday, August 24th. They set a “neutral” rating and a $230.00 target price on the stock. SVB Leerink cut their price target on Illumina from $225.00 to $220.00 and set a “market perform” rating on the stock in a research note on Friday, August 12th. Evercore ISI cut their price target on Illumina to $170.00 in a research note on Monday, August 15th. Finally, Cowen cut their price target on Illumina to $327.00 in a research note on Monday, August 15th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, Illumina has an average rating of “Hold” and an average price target of $257.27.

Insider Transactions at Illumina

In other news, SVP Alexander Aravanis sold 539 shares of the firm’s stock in a transaction dated Thursday, July 7th. The stock was sold at an average price of $200.00, for a total transaction of $107,800.00. Following the sale, the senior vice president now owns 3,346 shares of the company’s stock, valued at $669,200. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.13% of the stock is currently owned by insiders.

Illumina Profile

(Get Rating)

Illumina, Inc provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.

See Also

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMNGet Rating).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.